The U.S. Food and Drug Administration on Wednesday approved Johnson & Johnson's oral pill for psoriasis, the company said.

ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met ...

Adults with moderate to severe plaque psoriasis saw the greatest mean quality-of-life gains with biologic therapy whereas home phototherapy offered lower costs for patients and payers, according to a ...

By Sriparna Roy March 18 (Reuters) - The U.S. Food and Drug Administration has approved Johnson & Johnson's oral pill for ...

The FDA approved icotrokinra for adults and adolescents aged 12 years and older with moderate to severe plaque psoriasis, ...

Johnson & Johnson said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to ...

The FDA has approved the first oral interleukin (IL)-23-targeted therapy for plaque psoriasis, Johnson & Johnson announced. The approval of icotrokinra (Icotyde) stipulates use in adults and children ...

Johnson & Johnson (NYSE: JNJ) announced today that the U.S. Food and Drug Administration (FDA) has approved ICOTYDE™ (icotrokinra), an interleukin-23 (IL-23) receptor antagonist for the treatment of ...

FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic therapy or phototherapy, expanding systemic options beyond injectables.

The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J ...

Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.

This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic arthritis, ulcerative colitis, and Crohn’s disease.